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Introduction
According to the Centers for Disease Control and Prevention, 
both cancer and diabetes are among the leading causes of death 
in the United States (second and seventh, respectively).1 
Mortality rates are consistently rising in diabetic patients who 
are subsequently diagnosed with cancer.2 The incidence of 
patients with concurrent diabetes and cancer has been reported 
by clinicians for decades, and a link between diabetes and can-
cer has been postulated for nearly 80 years.3,4 However, it is 
only within the past decade that significant epidemiological 
evidence has been compiled to suggest a causal link.5,6 Risk for 
several cancer types, including cancers of the liver, pancreas, 
colorectum, urinary tract, breast, and female reproductive 
organs, is increased in diabetic patients.4,5 Moreover, diabetes 
increases metastasis, recurrence, and mortality of cancer.3,4 
Aberrant glucose metabolism in cancer cells is a result of pref-
erential aerobic glycolysis, referred to as the Warburg effect.7 
Thus, hyperglycemia promotes rapid cancer cell proliferation 
and contributes to rewiring of metabolic pathways for cell 
growth and survival.4,7 Currently, diabetes-cancer link has pri-
marily been hypothesized to rely on hormonal (insulin and 
insulin-like growth factor 1), inflammatory, and metabolic 
(hyperglycemia) characteristics of diabetes.8
A recent retrospective study showed that colorectal cancer 
patients with diabetes had higher local tumor malignancy than 
those with normal glucose.9 Clinically, glycemic control 
through diet and exercise has been shown to reduce the inci-
dence and improve the chance of survival in pancreatic cancer 
patients.10,11 Diabetes and obesity have also been linked to 
higher incidence of breast cancer.12 Insulin receptor and insu-
lin-like growth factor receptor are over-expressed in breast 
cancer which accounts for breast cancer proliferation and tum-
origenesis in type 2 diabetic patients. Survival of patients hav-
ing diabetes and breast cancer is very poor owing to different 
factors including delay in diagnosis, less intensive therapeutic 
regimen, and diabetes-related comorbidities.13 It is likely that 
hyperglycemic conditions are detrimental to cellular structure 
that increases the propensity of cancerous states. However, 
there is a lack of information currently on whether diabetes 
changes cell structure and function which predisposes cancer 
cells to an aggressive phenotype. We thus hypothesize that dia-
betes/hyperglycemic conditions induce changes in cytoskeletal 
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structure of breast cancer cells which accelerates breast cancer 
progression, and can possibly be used as a diagnostic marker.
Atomic force microscope (AFM) can be used for imaging 
biological cells and tissues, and has been used to measure surface 
forces between the AFM tip and sample surface.14 One of the 
valuable features of AFM for biological applications is the abil-
ity of investigating morphology of biological tissues/cells.15-19 
Biomechanical properties including cellular hardness, modulus 
of elasticity, and adhesion have been widely investigated using 
AFM.20,21 Atomic force microscope has also been used to dis-
tinguish cancer cells from normal cells based on their stiffness, 
growth, mechanics, and morphology.22-26 Optical and confocal 
microscopies are also used for imaging cells, but they cannot 
detect cells’ stiffness, mechanics, ultra-structure, and interaction 
between cells. The biomechanical properties of cancer cells have 
also been investigated.27-30 Lincoln and colleagues22,24 measured 
stiffness of human breast epithelial cells and breast cancer cells 
using optical stretcher and they showed normal cells are 5 times 
stronger than the cancer cells. Lekka et al23,31 investigated the 
modulus of elasticity of normal cells and cancer cells using 
AFM and they found higher modulus of elasticity for normal 
cells than breast cancer cells.
Cytoskeletons are internal polymer networks that not only 
give cells their shape and mechanical strength, but through their 
changes, especially their ability to withstand external and inter-
nal pressure, can also indicate the health of the cells. The 
cytoskeleton is a dynamic structure that changes through dif-
ferentiation of cells and their division, making it useful to study 
a variety of diseases.32 Here we aim to measure cytoskeletal elas-
ticity among different cancer cells and normal cells. Our study 
can indicate targets for cancer therapeutics as well as provide a 
source for diagnostic markers in staging cancer progression. In 
this article, we have used AFM with Bruker’s Sharp Microlever 
(MSNL) with conical probes to investigate the mechanical 
changes in cell architecture of benign epithelial cells (MCF-
10A) and those representing non-invasive, hormone-dependent 
breast cancer cells (MCF-7) and invasive, hormone-independ-
ent breast cancer cells (MDA-MB-231). These cells were 
exposed to normoglycemic (5 mM) or hyperglycemic/diabetic 
(25 mM glucose) concentrations. Differences in mechanical cell 
responses were measured using modulus of elasticity. It is hoped 
that this work may shed further light on the physiology of tis-
sues in patients with concurrent cancer and diabetes.
Materials and Methods
Cell culture and treatment
All cell lines (MCF-7, MDA-MB-231, and MCF-10A) were 
purchased from ATCC. Mammary epithelial cells (MCF-
10A) were grown in Dulbecco’s Modified Eagle Medium 
(DMEM)/F12 supplemented with 5% horse serum, 20 ng/mL 
epidermal growth factor (EGF), 0.5 μg/mL hydrocortisone, 
100 ng/mL cholera toxin, 10 ug/mL insulin, 100 IU/mL peni-
cillin, and 100 ug/mL streptomycin. Breast cancer cell lines 
(MCF-7 and MDA-MB-231) were grown in DMEM/F12 
media supplemented with 5% Foetal Bovine Serum (FBS), 
100 IU/mL penicillin, and 100 ug/mL streptomycin. Cells 
were grown in an incubator set at 37°C with a 5% CO2 air 
environment.
Cells were grown in chambered glass slides for microscopy 
and on 80% confluency, they were starved for 1 hour using 
phenol red-free, serum free media. The cells were then treated 
using the same media supplemented with different glucose 
treatment—normal glucose (5 mM), high glucose (25 mM). 
The 5-mM glucose treatment in all 3 cell lines was used as the 
control treatment to compare with all other treatments. Cells 
were incubated for 48 and 72 hours to monitor cell structure. 
In the “Results” section, the cells, MCF-7, MCF-10A, and 
MDA-MB-231, are labeled as C7, C10, and C231 in the 
resulting figures.
Preparation of samples for microscopy
After the incubation period, cells were washed with cold 1× 
PBS (Phosphate-buffered saline), and then incubated with 4% 
w/v formaldehyde solution (prepared in PBS) for 15 minutes at 
room temperature. Fixative solution was removed and cells 
were again washed 3 times with PBS. Cell mounting solution 
was added before placing coverslips on the wells and then the 
cells were imaged using microscopy.
Atomic force microscopy
Atomic force microscope MFP-3D (Oxford Instruments, 
Santa Barbara, California) equipped with MSNL silicon 
nitride AFM probes (Bruker, Santa Barbara, CA) was used to 
scan the cells. These AFM probe have several cantilevers. For 
imaging, contact mode was applied for cell imaging, and for 
force data collection, MSNL-F probes were used. The spring 
constant was calculated via the thermal method prior to each 
experiment and found to be 0.6 N/m. The cantilever’s reso-
nance frequency was between 85 and 155 kHz. Atomic force 
microscopy probe calibrations were made via indentation mode 
versus a PDMS gel sample acquired from Bruker (PDMS-
SOFT-1-12M, Bruker) prior to experimentation. This sample 
has a known Young’s modulus (2.5 MPa). Atomic force micros-
copy was used to image 3 different line of cells and also inden-
tation was performed above the cell surface. To analyze the 
indentation, the Igor Pro 6.23 software package was used, by 
which the Sneddon model was used to fit the force versus 
indentation curves. For both the PDMS reference samples and 
the cells, their Young’s modulus were recorded. Equation 1 is 
known as Sneddon model; where F is the force, E is Young’s 
modulus, α is half angle of the intender, ν is the Poisson ratio, 
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General data acquisition
Around 150 data points were collected, and 100 to 130 force 
curves were analyzed from them after filtration. The loading 
force used was in the range of 0.5 to 2 nN. Atomic force 
microscopy probe approach/retract rate was constant at 
300 nm/s in all experiments. Indentation was performed for 
more than 3 cells in each cell line. Arrows in the force map 
images below detail the location of measurement on the 
cells, which is in the center of the cell. Multiple Force Map 
measurements were carried out on different cells of the same 
sample and also with changing parameters (eg, trigger 
value). The differences observed are statistically significant 
based on the standard error (SE) values in each condition. 
Height measurements and roughness analysis were executed 
via FemtoScan.
Fluorescence microscopy
Cells were grown in chambered glass slides and processed for 
fluorescence microscopy for F-actin staining. After treatment, 
the media was removed, cells washed with PBS, and then 
incubated with 4% (w/v) formaldehyde solution for 15 min-
utes at room temperature. Fixative was then removed, washed 
again, and reincubated with 0.5% Triton X-100 (v/v) for per-
meabilization. After incubation for 15 minutes at room tem-
perature, cells were washed again and stained with Actin 
Green 488 Ready Probes reagent. Cells were counterstained 
with DAPI (4′,6-diamidino-2-phenylindole) for nucleus 
staining. Slides were incubated for 30 minutes, protected from 
light on which cells were again washed and then imaged with 
excitation/emission at 540/565 nm for actin staining using 
fluorescence microscopy.
Statistics
For statistical data analysis, t-test was performed for different 
cell lines with normal and high glucose treatment. A P value 
less than .05 indicates significance between treatments.
Results
For mechanical characterization, height map imaging was 
used to generate a picture of the cells. The morphologies of 
different cells at the time of analyses (48 hours) are shown in 
Figure 1. C10 (normal mammary epithelial) cells (Figure 1—
top, right) display a round, rather smooth surface, and are in 
clumps. The middle, top image in Figure 1 shows a height 
map of C7 cells (non-invasive breast cancer cells). A zoom-in 
below that figure shows the heterogeneous height of these 
cells, giving a rather crumpled appearance. Similar observation 
was noted for C231 (invasive breast cancer cells) cells in the 
height map (Figure 1—top, left). The zoomed-in region 
depicts nanometer non-uniformity along the surface. These 
tumorigenic breast cell lines (C231) represent hormone-inde-
pendent breast cancer cells. In contrast, C7 cells display irreg-
ular cell shapes and rough, overly porous, and non-uniform 
exteriors. An overall height map is given for each type in 
Figure 2. Respectively, the roughness values of MDA-MB-231, 
MCF-7, and MCF-10A cells in these images are 148.2, 113.5, 
and 345.4 nm, respectively (Figure 2). The maximum height 
was 1100 nm for MDA-MB-231 cell line, 1800 nm for 
MCF-7 cell line, and 4300 nm for MCF-10A cell line. These 
indicate substantial differences between each cell type, and by 
virtue of what the cancers or lack of cancer that they model, 
differences in disease state. This demonstrates and supports 
research that suggests surface and mechanical differences in 
states of malignancy.33-35
Figure 1. Atomic force microscopy of normal mammary epithelial cells (MCF-10A), non-invasive breast cancer cells (MCF-7), and invasive breast cancer 
cells (MDA-MB-231). The figures in the second row show a zoomed-in region, which depict nanometer non-uniformity along the surfaces. More than 10 
cells were imaged using atomic force microscopy in each cell line.
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On comparing the modulus of elasticity among the 3 cell 
types, the invasive cancer cells (C231) were found to be the 
least elastic while the normal cells (C10) were the most elastic 
(Figure 3). After 48 hours normal dose glucose (5 mM) treat-
ment, a differential modulus of elasticity can be observed with 
an increase in malignancy. The most striking difference was 
observed between the C10 and C231. The variance between 
non-invasive cancer cells (C7) and invasive cancer cells 
(C231) was much less. Further incubation (72 hours) in nor-
mal glucose magnified the difference in elasticity among the 
cell types, with C231 being the least elastic (Figure 4). 
Treatment with high glucose decreased elasticity in all cell 
types at 48 hours (Figure 3) with almost negligent values in 
cancer cells. At 72 hours, however, the cancer cells appear to 
show a slight increase in elasticity, which could be due to their 
highly proliferative nature in presence of glucose.
All cells, regardless of malignancy, exhibited higher modu-
lus of elasticity values with normal doses of glucose at 72 hours 
(Figure 4). In the case of cancer cells, C231 and C7, normal and 
high glucose dosing regimens showed differences of nearly 
3.22 and 1.88 times the modulus of elasticity, respectively. The 
difference in C10 under normal and high doses were nearly 
0.65 times the modulus of elasticity. Interestingly, normal doses 
of glucose yielded higher modulus of elasticity values for C10 
cells but not for cancer cells. At 48 hours, C231 and C7 exhib-
ited large differences in responses between normal and high 
































Figure 3. Comparison of modulus of elasticity measurement obtained 
using atomic force microscopy for all cell types. MDA-MB-231 (C231), 
MCF-7 (C7), and MCF-10A (C10), in normal glucose (5 mM, NG) treatment 






































Figure 4. Comparison of modulus of elasticity measurement obtained 
using atomic force microscopy for all cell types. MDA-MB-231 (C231), 
MCF-7 (C7), and MCF-10A (C10), in normal glucose (5 mM, NG) treatment 
and high dose glucose (25 mM, HG) treatment at 72 hours (n = 3, *P < .05).
Figure 2. Height mapping of MDA-MB-231, MCF-7, and MCF-10A cells.
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difference between C231 and C7 was marginal. At normal 
level of glycemic stress, modulus of elasticity values for the cells 
was reasonably high, but they showed a gradient with decreas-
ing elasticity from normal status to increasing malignancy. This 
trend was exacerbated over 72 hours, with the normal cell dis-
playing a high modulus while those of the cancerous cells 
dropped drastically (Figure 4). The hyperglycemic regimen 
yielded different results—only the normal cells had a high 
modulus at 48 hours. However, by 72 hours, the modulus for 
both cancerous cell types appear to decrease.
Fluorescent staining of actin filaments (Figure 5) depicts 
there is a clear decrease in actin with high glucose treatments at 
48 hours in all cell types. Interestingly, on longer incubation 
(72 hours) only a slight decrease in actin staining was observed 
in MDA-MB-231 and MCF-7, although MCF-10A cells dis-
play no change/slight increase.
Discussion and Conclusions
Based on the results, we support our initial hypothesis that dia-
betes affects the cytoarchitecture and thus tensile strength far 
more in cancerous mammary epithelial cells in comparison with 
normal mammary epithelial cells. Through both control and 
hyperglycemic regimens, cancerous cells exhibited far lower 
modulus of elasticity at 48 and 72 hours time points. Our results 
show that mechanical properties (elasticity) of breast cancer cells 
are quite distinct from normal epithelial cells and are further 
affected by diabetes. This was further supported by mechanical 
tests in which the modulus of elasticity of cells was decreased, 
contrasted with increased state of malignancy of cancer cells, 
regardless of glucose levels. In each case, the modulus of elastic-
ity was much higher for benign cells. However, under control 
regimens, the modulus of elasticity of C231 and C7 decreased 
between 48 and 72 hours while the reverse occurred for normal 
cells under hyperglycemic regimens. This suggests that the rela-
tionship contains complexities, which require further study.
Elasticity can affect how cells differentiate and divide, which 
has implications in the overall function of affected tissues and 
organs. One family of diseases in particular that could be 
affected by changes in cytoskeletons and thus cellular strength 
is cancer, a group of diseases that stem from the aberrant and 
uncontrolled division of cells. With changes that occur due to 
this affliction, the cytoskeleton can undergo many changes in 
its ability to withstand pressure. Prior research has indicated 
that the cytoskeleton plays a role in intracellular glucose 
metabolism.36,37 We believe that differing external glycemic 
stresses may impart a significant disruption of internal glucose 
metabolism leading to changes in cytoskeletal strength.
Atomic force microscopy images revealed heterogene-
ously organized surfaces, possibly reflecting sub-membrane 
cytoskeletal changes induced by diabetic stress. These 
changes suggest sporadic changes which need to be targeted 
for effective therapies. Remarkably, this could be observed 
under a relatively short period of time. Fluorescence micros-
copy data also corroborate our Young’s modulus observation, 
that in general, the cancerous cells have lower actin (thus 
lower Young’s modulus of elasticity), and high glucose expo-
sure further decreases actin and elasticity. These characteris-
tics will be further explored to design a microfluidic device to 
segregate different cell types, which can provide a novel, 
rapid, and economical diagnostic tool in diabetic oncology. 
Diagnostic tools examining patients who concurrently have 
cancer and diabetes can benefit from consideration of how 
their mechanism of more pliable cells and tissues factor into 
treatment. This benefit may be improved as more 3-dimen-
sional systems are adapted in the future.
Future Work
As a preliminary work, this article demonstrates at the least that 
one can probe structural changes in breast cells in response to 







Figure 5. F-actin staining in different cell types: MDA-MB-231 (C231), MCF-7 (C7), and MCF-10A (C10) in normal glucose (5 mM, NG) treatment and high 
glucose (25 mM, HG) treatment at 48 and 72 hours (n = 3, *P < .05). White arrows indicate actin fibers (red) and blue stained structures are the nuclei. Each 
image is representative of 5 independent experiments.
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substantial conclusions, experiments will need to assay cell and 
cell-cell properties in increasingly biomimetic conditions that 
extend from the cell outward to its environment and interac-
tions with proximal cells. This entails moving up to the orga-
noid, and eventually the organ system level. This work will be 
helpful as the research community works upward.
Author Contributions
DD designed and the performed research, analyzed data, and 
contributed to the manuscript. X-LP analyzed data and con-
tributed to the manuscript. JO-R was involved with cell cul-
ture, glucose treatments, and preparing samples for AFM. 
VB was involved with the cell culture and preparing samples 
for AFM. IGD contributed to the manuscript. SC designed 
the research, supervised the work, and contributed to the 
manuscript.
ORCID iD
Surabhi Chandra  https://orcid.org/0000-0003-1403-2911
ReFeRenCes
 1. Murphy SL, Xu J, Kochanek KD. Deaths: Final Data for 2010, in National Vital 
Statistics Report. Atlanta, GA: Centers for Disease Control and Prevention; 
2013.
 2. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer 
patients with preexisting diabetes mellitus: a systematic review and meta-analy-
sis. JAMA. 2008;300:2754-2764.
 3. Chowdhury TA. Diabetes and cancer. QJM. 2010;103:905-915.
 4. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus 
report. CA Cancer J Clin. 2010;60:207-221.
 5. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Dia-
betes and cancer I: risk, survival, and implications for screening. Cancer Causes 
Control. 2012;23:967-981.
 6. Onitilo AA, Stankowski RV, Berg RL, et al. Breast cancer incidence before and 
after diagnosis of type 2 diabetes mellitus in women: increased risk in the predia-
betes phase. Eur J Cancer Prev. 2014;23:76-83.
 7. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progres-
sion. Diabetes Metab J. 2014;38:330-336.
 8. Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: associations, mechanisms, and 
implications for medical practice. World J Diabetes. 2014;5:372-380.
 9. Cui G, Zhang T, Ren F, et al. High blood glucose levels correlate with tumor 
malignancy in colorectal cancer patients. Med Sci Monit. 2015;21:3825-3833.
 10. Giovannucci E, Michaud D. The role of obesity and related metabolic distur-
bances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 
132:2208-2225.
 11. Krone CA, Ely JT. Controlling hyperglycemia as an adjunct to cancer therapy. 
Integr Cancer Ther. 2005;4:25-31.
 12. Tomas NM, Masur K, Piecha JC, Niggemann B, Zanker KS. Akt and phospho-
lipase Cgamma are involved in the regulation of growth and migration of MDA-
MB-468 breast cancer and SW480 colon cancer cells when cultured with 
diabetogenic levels of glucose and insulin. BMC Res Notes. 2012;5:214.
 13. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer out-
comes: a systematic review and meta-analysis. J Clin Oncol. 2011;29:40-46.
 14. Dutta D, Schmidt R, Fernando SC, Dastider IG. A comparative study of force 
measurements in solution using micron and nano size probe. World J Nano Sci 
Eng. 2020;9:1-14.
 15. Dutta D, Asmar A, Stacey M. Effects of nanosecond pulse electric fields on cel-
lular elasticity. Micron. 2015;72:15-20.
 16. Dutta D, Palmer XL, Asmar A, Stacey M, Qian S. Nanosecond pulsed electric 
field induced changes in cell surface charge density. Micron. 2017;100:45-49.
 17. Dutta D, Palmer XL, Kim J, Qian S, Stacey M. Energy dissipation mapping of 
cancer cells. Micron. 2018;105:24-29.
 18. Dutta D, Russell C, Kim J, Chandra S. Differential mobility of breast cancer 
cells and normal breast epithelial cells under DC electrophoresis and electroos-
mosis. Anticancer Res. 2018;38:5733-5738.
 19. Soma P, Pretorius E. Interplay between ultrastructural findings and athero-
thrombotic complications in type 2 diabetes mellitus. Cardiovasc Diabetol. 
2015;14:96.
 20. Hossan MR, Dutta D, Islam N, Dutta P. Review: electric field driven pumping 
in microfluidic device. Electrophoresis. 2018;39:702-731.
 21. Radmacher M, Fritz M, Kacher CM, Cleveland JP, Hansma PK. Measuring the 
viscoelastic properties of human platelets with the atomic force microscope. Bio-
phys J. 1996;70:556-567.
 22. Guck J, Schinkinger S, Lincoln B, et al. Optical deformability as an inherent cell 
marker for testing malignant transformation and metastatic competence. Biophys 
J. 2005;88:3689-3698.
 23. Lekka M, Laidler P, Gil D, Lekki J, Stachura Z, Hrynkiewicz AZ. Elasticity of 
normal and cancerous human bladder cells studied by scanning force microscopy. 
Eur Biophys J. 1999;28:312-316.
 24. Lincoln B, Erickson HM, Schinkinger S, et al. Deformability-based flow 
cytometry. Cytometry A. 2004;59:203-209.
 25. Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater. 
2007;3:413-438.
 26. Thoumine O, Ott A. Comparison of the mechanical properties of normal and 
transformed fibroblasts. Biorheology. 1997;34:309-326.
 27. Suresh S. Nanomedicine: elastic clues in cancer detection. Nat Nanotechnol. 
2007;2:748-749.
 28. Suresh S, Spatz J, Mills JP, et al. Connections between single-cell biomechanics 
and human disease states: gastrointestinal cancer and malaria. Acta Biomater. 
2005;1:15-30.
 29. Taatjes DJ, Sobel BE, Budd RC. Morphological and cytochemical determina-
tion of cell death by apoptosis. Histochem Cell Biol. 2008;129:3333-4343.
 30. Li QS, Lee GY, Ong CN, Lim CT. AFM indentation study of breast cancer 
cells. Biochem Biophys Res Commun. 2008;374:609-613.
 31. Lekka M, Laidler P, Ignacak J, et al. The effect of chitosan on stiffness and 
glycolytic activity of human bladder cells. Biochim Biophys Acta. 2001;1540: 
127-136.
 32. Guck J, Schinkinger S, Lincoln B, et al. Optical deformability as an inherent cell 
marker for testing malignant transformation and metastatic competence. Biophys 
J. 2005;88:3689-3698.
 33. Lee TK, Tchvialeva L, Zeng H, Mclean DI, amp; Lui H. Laser speckle and skin can-
cer: Skin roughness assessment. In: Ninth International Conference on Correlation 
Optics; 2009. https://www.spiedigitallibrary.org/conference-proceedings-of-spie/ 
7388/738816/Laser-speckle-and-skin-cancer-skin-roughness-assessment/10. 
1117/12.854001.short?SSO=1.
 34. Connemann BJ, Busche H, Kreusch J, Teichert H, Wolff HH. Quantitative sur-
face topography as a tool in the differential diagnosis between melanoma and 
naevus. Skin Res Technol. 1995;1:180-186.
 35. Wang Y, Xu C, Jiang N, et al. Quantitative analysis of the cell-surface roughness 
and viscoelasticity for breast cancer cells discrimination using atomic force 
microscopy. Scanning. 2016;38:558-563.
 36. Liu Z, Zhang Y, Chang Y, Fang F. The role of cytoskeleton in glucose regulation. 
Biochemistry (Moscow). 2006;71:476-480.
 37. Heaslip AT, Nelson SR, Lombardo AT, Beck Previs S, Armstrong J, Warshaw 
DM. Cytoskeletal dependence of insulin granule movement dynamics in INS-1 
beta-cells in response to glucose. PLoS ONE. 2014;9:e109082.
